Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Cetera Advisor Networks LLC

Share on StockTwits

Cetera Advisor Networks LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 0.7% in the third quarter, Holdings Channel.com reports. The fund owned 124,747 shares of the company’s stock after purchasing an additional 815 shares during the period. Cetera Advisor Networks LLC’s holdings in Merck & Co., Inc. were worth $10,486,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Fox Run Management L.L.C. lifted its stake in Merck & Co., Inc. by 4.4% in the third quarter. Fox Run Management L.L.C. now owns 2,827 shares of the company’s stock worth $238,000 after acquiring an additional 118 shares during the last quarter. First Command Bank lifted its stake in Merck & Co., Inc. by 1.4% in the third quarter. First Command Bank now owns 8,599 shares of the company’s stock worth $724,000 after acquiring an additional 118 shares during the last quarter. Allworth Financial LP lifted its stake in Merck & Co., Inc. by 1.9% in the third quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock worth $528,000 after acquiring an additional 119 shares during the last quarter. Stillwater Investment Management LLC lifted its stake in Merck & Co., Inc. by 2.6% in the second quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock worth $402,000 after acquiring an additional 120 shares during the last quarter. Finally, Southeast Asset Advisors Inc. lifted its stake in Merck & Co., Inc. by 2.3% in the second quarter. Southeast Asset Advisors Inc. now owns 5,349 shares of the company’s stock worth $449,000 after acquiring an additional 120 shares during the last quarter. Institutional investors and hedge funds own 74.64% of the company’s stock.

A number of research analysts recently issued reports on MRK shares. Credit Suisse Group reiterated a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. Societe Generale set a $105.00 price target on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. set a $96.00 price target on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, October 10th. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Barclays restated a “sell” rating and set a $85.00 price objective on shares of Merck & Co., Inc. in a research report on Tuesday. Two analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the company. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus price target of $95.06.

Shares of NYSE:MRK opened at $84.12 on Wednesday. The firm has a 50 day simple moving average of $83.93 and a 200-day simple moving average of $82.92. The company has a market capitalization of $212.82 billion, a PE ratio of 19.38, a P/E/G ratio of 1.81 and a beta of 0.54. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $87.35. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 0.84.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.27. The business had revenue of $12.40 billion for the quarter, compared to analysts’ expectations of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The company’s quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.19 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ocean Protocol  Trading Up 44.8% Over Last 7 Days
Ocean Protocol Trading Up 44.8% Over Last 7 Days
Deutsche eMark  1-Day Volume Tops $66.00
Deutsche eMark 1-Day Volume Tops $66.00
Paytomat Hits 24-Hour Trading Volume of $74,234.00
Paytomat Hits 24-Hour Trading Volume of $74,234.00
CanYaCoin  24 Hour Volume Tops $3,002.00
CanYaCoin 24 Hour Volume Tops $3,002.00
Analysts Set Encompass Health Corp  Price Target at $71.75
Analysts Set Encompass Health Corp Price Target at $71.75
Companhia Paranaense de Energia  Given Consensus Recommendation of “Hold” by Analysts
Companhia Paranaense de Energia Given Consensus Recommendation of “Hold” by Analysts


 
© 2006-2019 Zolmax.